About: Immunogenicity and protective efficacy of recombinant fusion proteins containing spike protein of infectious bronchitis virus and hemagglutinin of H3N2 influenza virus in chickens

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immunogenicity and protective efficacy of recombinant fusion proteins containing spike protein of infectious bronchitis virus and hemagglutinin of H3N2 influenza virus in chickens Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Immunogenicity and protective efficacy of recombinant fusion proteins containing spike protein of infectious bronchitis virus and hemagglutinin of H3N2 influenza virus in chickens
Creator	Cao, Yongchang Xue, Chunyi Wang, Wei Wei, Ying Yin, Lijuan Zeng, Yuyao
Source	Elsevier; Medline; PMC
abstract	Abstract Infectious bronchitis (IB) is an acute and highly contagious viral respiratory disease of chickens and vaccination is the main method for disease control. The S1 protein, which contains several virus neutralization epitopes, is considered to be a target site of vaccine development. However, although protective immune responses could be induced by recombinant S1 protein, the protection rate in chickens was still low (<50%). Here, we generated fused S1 proteins with HA2 protein (rS1-HA2) or transmembrane domain and cytoplasmic tail (rS1-H3(TM)) from hemagglutinin of H3N2 influenza virus. After immunization, animals vaccinated with fusion proteins rS1-HA2 and rS1-H3(TM) demonstrated stronger robust humoral and cellular immune responses than that of rS1 and inactivated M41 vaccine. The protection rates of groups immunized with rS1-HA2 (87%) were significantly higher than the groups inoculated with rS1 (47%) and inactivated M41 vaccine (53%). And chickens injected with rS1-H3(TM) had similar level of protection (73%) comparing to chickens vaccinated with rS1 (47%) (P=0.07). Our data suggest that S1 protein fused to the HA2 or TM proteins from hemagglutinin of H3N2 influenza virus may provide a new strategy for high efficacy recombinant vaccine development against IBV.
has issue date	2016-09-02(xsd:dateTime)
bibo:doi	10.1016/j.virusres.2016.07.010
bibo:pmid	27497621
has license	els-covid
sha1sum (hex)	df2e53b25082a4e53014a171f7f255ba30363874
schema:url	https://doi.org/10.1016/j.virusres.2016.07.010
resource representing a document's title	Immunogenicity and protective efficacy of recombinant fusion proteins containing spike protein of infectious bronchitis virus and hemagglutinin of H3N2 influenza virus in chickens
has PubMed Central identifier	PMC7114550
has PubMed identifier	27497621
schema:publication	Virus Research
resource representing a document's body	covid:df2e53b25082a4e53014a171f7f255ba30363874#body_text
is schema:about of	named entity 'INFECTIOUS BRONCHITIS VIRUS' named entity 'HEMAGGLUTININ' named entity 'humoral' named entity 'proteins' named entity 'data' named entity 'vaccinated' named entity 'protein' named entity 'protein' named entity 'ACUTE' named entity 'RECOMBINANT' named entity 'PROTEIN ' named entity 'HIGHLY' named entity 'TRANSMEMBRANE DOMAIN' named entity 'VACCINE DEVELOPMENT' named entity 'PROTEIN' named entity 'COMPARING' named entity 'ROBUST' named entity 'RS1' named entity 'VACCINE' named entity 'PROVIDE' named entity '28P' named entity '2887' named entity 'METHOD' covid:arg/df2e53b25082a4e53014a171f7f255ba30363874 named entity 'RESPIRATORY DISEASE' named entity 'CYTOPLASMIC TAIL' named entity 'IMMUNIZATION' named entity 'LOW' named entity 'VACCINATION' named entity 'HA2' named entity 'SIMILAR' named entity 'VIRUS NEUTRALIZATION' named entity 'COULD BE' named entity 'INFECTIOUS BRONCHITIS' named entity 'GENERATED' named entity 'CHICKENS' named entity 'SUGGEST' named entity 'SPIKE PROTEIN' named entity 'EFFICACY' named entity 'MAIN' named entity 'SITE OF' named entity 'STRATEGY' named entity 'DEMONSTRATED' named entity 'DISEASE CONTROL' named entity 'TARGET SITE' named entity 'ANIMALS' named entity 'CONTAINS' named entity 'HERE' named entity 'RECOMBINANT FUSION PROTEINS' named entity 'CHICKENS' named entity 'IMMUNOGENICITY' named entity 'CONTAINING' named entity 'INFLUENZA VIRUS' named entity 'GROUPS' named entity 'PROTEINS' named entity 'OUR' named entity 'H3N2 INFLUENZA' named entity 'LEVEL' named entity 'IMMUNIZED' named entity 'H3N2 INFLUENZA' named entity 'INFLUENZA VIRUS' named entity 'IBV' named entity 'PROTEIN ' named entity 'CELLULAR' named entity 'IMMUNE RESPONSES' named entity 'CONSIDERED' named entity '0.07' named entity 'NEW' named entity 'HIGH' named entity 'RECOMBINANT VACCINE' named entity 'VACCINATED' named entity 'EFFICACY' named entity 'INDUCED' named entity 'PROTEIN FUSED' named entity 'VIRAL' named entity 'PROTECTION'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software